Keywords
Maxillofacial region
Sclerotherapy
Venous malformations
Vascular anomalies
How to Cite
Abstract
Objective
To evaluate the efficacy of intralesional bleomycin in the management of venous malformations of the maxillofacial region.
Study Design
Cross-sectional study.
Place and Duration of Study Department of Oral and Maxillofacial Surgery, Mardan Medical Complex, from July 2024 to Dec 2024.
Methodology
A total of 91 patients were included who exhibited radiologically and clinically proven venous anomalies of the craniofacial region. Patients of either gender who gave written informed consent and had not gotten proper therapy for venous abnormalities before were eligible to participate. Patients who were not eligible for bleomycin due to serious medical conditions were not included. The dosage of intralesional bleomycin was 0.3-0.6 mg/kg, with a maximum of 1 mg/kg per session, and it was given over the course of three to four sessions spaced three weeks apart. Lesson size reduction, as documented by serial photography and direct measurement, served as an indicator of clinical response. The data was examined using SPSS version 24, with gender and age groups being the dividing lines.
Results
The mean age of participants was 34.56 ± 14.88 years. Complete response was observed in 50.5% of patients, considerable response in 28.6%, partial response in 14.3%, and no response in 6.6%. There was no statistically significant association between clinical response and age (P = 0.844) or gender (P = 0.762).
Conclusion
Intralesional bleomycin is an effective treatment modality for venous malformations of the maxillofacial region, demonstrating significant efficacy with minimal complications.